Newsroom

PPTA Press Releases

A missed opportunity to acknowledge EU’s dependency on U.S. plasma

Brussels, Belgium (December 17) The Plasma Protein Therapeutics Association (PPTA) regrets that the publication of the European Commission report, “Study on medicine shortages,” does not include plasma, which is a biological starting material for the manufacture of lifesaving plasma-derived medicinal products (PDMPs). PDMP availability is primarily dependent on volumes of plasma collected, which are currently insufficient to meet the needs of EU patients.

Continue reading

Adoption of the EP report “EU Pharmaceutical Strategy”

Brussels, Belgium (November 24) — The Plasma Protein Therapeutics Association (PPTA) congratulates MEP Montserrat (EPP, Spain) for the adoption of the report “EU Pharmaceutical Strategy” during the European Parliament’s Plenary session. The report was adopted by 527 MEPs on Wednesday 24 November.

Continue reading

International Plasma Awareness Week 2021: Donate Plasma. Save Lives.

ANNAPOLIS, MD (October 4, 2021) — The Plasma Protein Therapeutics Association (PPTA) is proud to mark the launch of the ninth annual International Plasma Awareness Week (IPAW), which will run from Monday, October 4 until Friday, October 8. Nearly 125,000 people in the U.S. with rare diseases, and countless others facing trauma and emergency medical needs every day, rely on medicines that are only available because of the commitment of dedicated plasma donors. Considering the nearly 20% decline in plasma donations seen last year due to the ongoing pandemic, the need for plasma donors is now more urgent than ever before. 

Continue reading

Calling on EU Policymakers to Increase Plasma Donations

Brussels, (October 4, 2021) — The Plasma Protein Therapeutics Association (PPTA) is marking the 9th annual International Plasma Awareness Week (IPAW), October 4-8, by increasing awareness and understanding about the importance of plasma, particularly the urgent need to increase plasma donations in the European Union, while also recognizing and thanking plasma donors who save and improve the lives of patients who rely on plasma for their therapies. Considering the revision of the European blood and tissues and cells legislation, PPTA calls on policymakers and regulators throughout Europe to strengthen its legal framework to benefit plasma donations for plasma-derived medicines and encourage new approaches that increase the collection of plasma across the European Union.

Continue reading

 

View more PPTA Press Releases

PPTA Statements

PPTA Statement on the Ukraine Crisis

The Plasma Protein Therapeutics Association (PPTA) expresses serious concern about the ongoing hostilities in Ukraine and the devastating impact on the lives of people in the region. As an association representing plasma collectors and manufacturers dedicated to saving and improving human lives, our primary focus remains on ensuring that patients have access to the essential plasma-derived treatments they rely on. Our member companies are making every effort to secure access for patients in the affected region during the conflict and in its aftermath.

Continue reading

PPTA Leadership Update – Amy Efantis

Dear PPTA Members and Patient Stakeholders,

We are writing to you today to inform you that Amy Efantis, PPTA’s president & CEO, recently informed the Global Board of Directors of her decision to leave the association. Her last day was Tuesday, February 15. We appreciate Amy’s contributions to PPTA in her time leading the association and wish her well in her future pursuits.

Continue reading

PPTA Disagrees with Ruling from Romanian Competition Council

The Plasma Protein Therapeutics Association (PPTA) disagrees with the 15 February 2022 ruling from the Romanian Competition Council (RCC) finding that PPTA directed manufacturers to withhold immunoglobulin (Ig) therapies from the Romanian market to force repeal of the so-called “clawback” tax. This conclusion is not supported by the RCC’s own investigation, which produced no evidence that company withdrawals from the Romanian market were the result of anything other than independent business decisions.

Continue reading

Plasma donations remain disappointingly low through ongoing pandemic, risking patients’ lives

The Plasma Protein Therapeutics Association (PPTA) is aware of emerging reports regarding patients not having reliable access to lifesaving plasma-derived therapies used to treat a variety of serious, rare, and chronic conditions caused by missing or deficient proteins in their blood. While there could be many reasons for these access challenges, the fact remains that for most of these conditions, plasma is the only starting material for effective therapies.

Continue reading

PPTA Responds to ProPublica Article

An article published by ProPublica on June 24 (“The U.S. Is Closing a Loophole That Lured Mexicans Over the Border to Donate Blood Plasma for Cash”) is the latest sensationalized reporting from ProPublica and ARD German TV reporters who continue to misrepresent and malign U.S. policies regarding plasma donation as well as the scores of committed individuals who cross the U.S.-Mexico border to donate their plasma. Tens of thousands of people safely donate their plasma every day in the U.S., with every donation directly contributing to helping nearly 125,000 Americans with serious and often life-threatening conditions live healthy and normal lives, as well as countless others facing trauma and emergency medical needs every day.

Continue reading

 

View more PPTA Statements

 

The Source Magazine (2021-2016)

The Plasma Pool

Infusion Banner Waves1

What Does the COVID-19 Vaccine Mean for Plasma Donation?
March 2021

Continue reading

What We Know Now about the “Kawasaki-Like” Syndrome
May 2020

Continue reading

 

Media inquiries

Europe
Faraz Kermani
Head of Global Communications
FKermani@pptaglobal.org

North America
Mathew Gulick
Senior Director, Lead for U.S. Communications
mgulick@pptaglobal.org

Copyright © 2020 PPTA. All rights reserved. (202) 789-3100